{
    "clinical_study": {
        "@rank": "141343", 
        "acronym": "PITA 3", 
        "arm_group": [
            {
                "arm_group_label": "treatment", 
                "arm_group_type": "Experimental", 
                "description": "Prospective randomized double blind, placebo controlled,  protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Prospective randomized double blind, placebo controlled,  protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of the protocol is to evaluate the efficacy of a protocol for induction\n      of tolerance to peanut ingestion increasing doses. The secondary purpose is to determine the\n      interest of a prolonged maintenance therapy"
        }, 
        "brief_title": "Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peanut Allergy", 
        "condition_browse": {
            "mesh_term": "Peanut Hypersensitivity"
        }, 
        "detailed_description": {
            "textblock": "Prospective randomized double blind, placebo controlled,  protocol in two phases: 1/ active\n      treatment versus placebo for induction phase; 2/ long versus short maintenance"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adolescents between 12 and 18 years\n\n          -  Clinical History of allergic manifestation within one hour of ingestion of peanuts or\n             Double-Blind, Placebo-Controlled Food Challenges (DBPCFCs) peanut positive below the\n             threshold of 2 grams\n\n          -  Bad reaction peanut demonstrated by positive Patch Test (PT \u2265 3 mm above the negative\n             control) and specific IgE f13> 12 IU / mL and / or rAra h2> 5.8 IU / mL\n\n          -  Previous follow at least 1 year\n\n        Exclusion Criteria:\n\n          -  Lack of response during the initial DBPCFCs to the cumulative dose of 2 grams of\n             peanut or instant dose of 1 gram of peanut\n\n          -  Uncontrolled asthma and / or severe over the previous year\n\n          -  Atopic dermatitis uncontrolled\n\n          -  Initial severe anaphylaxis requiring hospitalization in intensive care\n\n          -  Presence of a major allergy with anaphylaxis at another allergen risk (milk, egg,\n             nuts, or other)\n\n          -  Home away from a center could support a severe reaction in emergency\n\n          -  Lack of motivation and understanding of parents and / or child\n\n          -  Incapacity\n\n               -  to establish a daily logbook of clinical monitoring\n\n               -  to support severe reaction after eating peanut\n\n               -  to follow a regular peanut ingestion protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046083", 
            "org_study_id": "CHU-0177", 
            "secondary_id": "2013-A00169-36"
        }, 
        "intervention": {
            "arm_group_label": "treatment", 
            "intervention_name": "arachid", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Teenager", 
            "Peanut", 
            "OIT (Oral Induction Tolerance)"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "placarin@chu-clermontferrand.fr", 
                "last_name": "Patrick LACARIN", 
                "phone": "0473751195"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont-Ferrand", 
                    "country": "France", 
                    "zip": "63003"
                }, 
                "name": "CHU Clermont-Ferrand"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers", 
        "overall_contact": {
            "email": "placarin@chu-clermontferrand.fr", 
            "last_name": "Patrick LACARIN", 
            "phone": "04 73 75 11 95"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Clermont-Ferrand", 
            "last_name": "Jean-Luc FAUQUERT", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients which tolerate the cumulative dose of 2 grams of peanut at the end of the first phase of 24 weeks between treatment and placebo groups", 
            "safety_issue": "Yes", 
            "time_frame": "at 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046083"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients had quadrupled their tolerance to peanut at the end of induction phase", 
                "safety_issue": "Yes", 
                "time_frame": "at 24 weeks"
            }, 
            {
                "measure": "Percentage of patients with adverse effects during induction phase", 
                "safety_issue": "Yes", 
                "time_frame": "at 24 weeks"
            }, 
            {
                "measure": "Modifications of the immune profile showing a desensitization to peanut", 
                "safety_issue": "Yes", 
                "time_frame": "at 24 weeks"
            }, 
            {
                "measure": "Percentage of patients which tolerate the cumulative dose of 2 grams of peanut during a Double-Blind, Placebo-Controlled Food Challenges (DBPCFCs) after 24 weeks without traces eviction diet after the end of maintenance phase", 
                "safety_issue": "Yes", 
                "time_frame": "at 24 weeks"
            }
        ], 
        "source": "University Hospital, Clermont-Ferrand", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Clermont-Ferrand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}